Skip links

Technology Can’t Solve All the Problems of COVID-19. But It’s Solving Many of Them

Jump To Section

Technology won’t solve all of the challenges presented by the spread of COVID-19, but it will alleviate some big obstacles.

Tech’s COVID-19 Impact: Remote Work, Telehealth, Virtual Learning, Global Connectivity

Technology won’t solve all of the challenges presented by the spread of COVID-19, but it will alleviate some big obstacles.

While the necessary measures of shutting down communities and suspending gatherings will have a devastating economic impact on some industries, others will continue on, albeit in an altered state. They can minimize disruption and power work from home so their companies don’t come to a standstill. Technology makes that possible.

Technology built on a robust communications network is delivering continuity in ways that simply would not have been possible 10 years ago.

Here are just some examples of how technology is helping:

Large scale work from home and remote collaboration. Though less than 4% of workers worked remotely full time before the COVID-19 pandemic, we’re now seeing how effective working from home can be on a much larger scale across a variety of industries. Collaboration tools from Zoom to Slack to Microsoft Teams, shared documents, VPNs, and more enable distant team members to work together.

Online K-12 and college classes. Some are using online learning platforms, some are using Google Classroom or even just YouTube. But the real challenge is connectivity and equity for students who don’t have internet access at home. While just 4% of students were enrolled exclusively in distance learning courses in higher ed, now it’s every college student at a number of major universities.

Telehealth services, intervention, monitoring. Doctors can assess patients and track symptoms remotely using telehealth options, and CMS even announced an expansion of Medicare telehealth services to help fight the virus. A number of apps also offer doctor visits to the uninsured. Two challenges remain: capacity and access.

Global community engagement and communication via social networks. Doctors are using Facebook Groups to ask questions and share advice for how to handle the pandemic. Sharing of news, memes, and ideas for how to help during the crisis has given the general public an outlet for their creativity and need to connect. Brands have been using social media to stay connected to their customers and suggest ways to support local businesses during the crisis.

Bringing gym training sessions into the home. Gyms are hosting classes in everything from meditation to yoga to strength training and more, broadcast over Zoom and other platforms.

Virtual tours. Dozens of museums around the world have free online tours of their exhibits. Zoos and aquariums are offering live feeds of their animals. Even theme parks have virtual tours of their attractions.

Tech vs. COVID-19: Tracking, Modeling, Mitigating Impact

Technology has also been crucial in fighting the virus. Doctors, scientists, and government officials have been utilizing data to track and monitor the spread of COVID-19 and disseminate that knowledge on a global scale. Health experts and governments have been learning in real time and using data to model what will happen to health systems if practices to flatten the curve are not enacted.

The confluence of technology, communications, and data is helping humanity to understand, plan, and react faster than in the past. It should be reassuring that we are quickly learning about the origins of the virus, tracking its spread across the globe, and evaluating the effectiveness of other countries’ responses. All of that is informing proactive measures to mitigate the spread of COVID-19.

Technology, of course, can’t solve every problem. Plenty of industries and workers are hurting right now, and technology won’t help. But it is aiding progress in fighting the spread of the virus and has softened the blow that social distancing and business closures have had on the economy. When we get to the other side of this crisis, hopefully technology will help get every industry back up to speed.

Stay safe, keep calm, and don’t forget to wash your hands.

Picture of Jeff Fleischman

Jeff Fleischman

Latest Reads


Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes